Eisai and Biogen launch LEQEMBI Pen, a weekly at‑home Alzheimer’s injection, in Japan
Eisai Co. and Biogen announced the launch of LEQEMBI Pen, a subcutaneous autoinjector of lecanemab, in Japan on 12 Nov 2026. The pen delivers 500 mg once weekly using two pens and is priced at 27,141 JPY per pen under the National Health Insurance list. Approval for the subcutaneous route was granted in Japan on 16 Sep 2026, making Japan the second market after the United States to receive the formulation.
Why it matters
Biogen says the at‑home pen could cut clinic visits and lower healthcare‑resource use, which may broaden patient uptake. The new administration option adds a revenue stream for both companies as they co‑commercialize the product.
Key facts
- 1The launch was announced on 12 Nov 2026. investors.biogen.com
- 2LEQEMBI Pen is priced at 27,141 JPY per pen in Japan’s National Health Insurance list. investors.biogen.com
- 3The pen delivers a total weekly dose of 500 mg lecanemab using two 1.25 mL pens. investors.biogen.com
- 4Japanese regulatory approval for the subcutaneous formulation was received on 16 Sep 2026. investors.biogen.com
- 5Eisai leads development and both companies will co‑commercialize the product. investors.biogen.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.